Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer

RCT of 682 patients with stage IB to IIIA EGFR mutation–positive non–small-cell lung cancer, reported longer disease-free survival at 24 months among those who received osimertinib vs placebo (90% vs 44%; HR, 0.17; 99% CI, 0.11 to 0.26; P<0.001) with no new safety concerns.


New England Journal of Medicine